The SENSOR Study: A Mixed-methods Study of SElf-management Checks to Predict exacerbatioNs of Pseudomonas Aeruginosa in Patients With Long-term reSpiratORy Conditions

Learn more about:
Related Clinical Trial
The Role of Airway Microbiota on Clinical Phenotypes and Disease Severity in Bronchiectasis Investigating the Clinical Features and Prognosis of Bronchiectasis Adult Patients Microbial Colonization Distribution and Adaptive Evolution of Lower Respiratory Tract in Bronchiectasis Patients. Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis Is a Single Daily Session Combining HS and ACTs Sufficient to Obtain Long-term Clinical Benefits in Bronchiectasis? Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections Investigation of Dynamic Hyperinflation and Its Relationship With Functional Exercise Capacity in Children With Bronchiectasis COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2 Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Diseases Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease Trial on The Efficacy of Hypertonic Saline on Non-CF CSLD. Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients With Bronchiectasis Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations A Series of N-of-1 Trials of Traditional Chinese Medicine Based on Bayesian Method A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation Efficacy and Safety of An’Ningpai Expectorant in Non-CF Bronchiectasis COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic Identification of Microbiome of Bronchiectasis in Chinese Population. Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19) Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound COPD Patient-Powered Research Network Can we Reduce Hospital Attendance Without Compromising Care by the Use of Telephone Consultation Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis Seoul National University Airway Registry VX-770 for the Treatment of Chronic Bronchitis Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis Adherence to Airway Clearance. Novel Approaches to Improving Adherence Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Prevalence of Respiratory Impairment During IBD The SENSOR Study: A Mixed-methods Study of SElf-management Checks to Predict exacerbatioNs of Pseudomonas Aeruginosa in Patients With Long-term reSpiratORy Conditions The Effect of Proprioceptive Neuromuscular Facilitation (PNF) Technique for Children With Chronic Pulmonary Diseases. Effect of HFCWO Vests on Spirometry Measurements Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study Evaluating the Effects of Traditional Chinese Medicine by N-of-1 Trials A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects Biological Determinants of Sputum Rheology in Chronic Airway Diseases A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device Efficacy and Safety Study of a Percussion Device to Mobilise Sputum From Respiratory Passage ATP and Capsaicin Cough Provocation Test in Chronic Cough and Bronchiectasis Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo Lung Clearance Index (LCI) in Pediatric Patients With Obstructive Lung Disease The Prevalence of Gastro-oesophageal Reflux in Chronic Lung Disease High Dose Inhaled Mannitol Study Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa Respiratory Muscle Strength in Bronchiectasis: Repeatability and Reliability Longitudinal Study of Helium-3 and Xenon-129 Magnetic Resonance Imaging The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) Evaluation Of The Lung Microbiome In NTM Bronchiectasis Inhalation Flow Rate-study Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis Procalcitonin-Guided Antibiotic Therapy in Bronchiectasis Inspiratory Flow and Volumes in Bronchiectatics Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD Evaluation of Periodontal Treatment in Patients With Bronchiectasis Long Term Nebulised Gentamicin in Patients With Bronchiectasis Comparison of PR Efficiency in Home-based With Hospital-based PR in Bronchiectasis Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis. Study of the Effect of FLUTTER® VRP1 (PEP and Oscillating High Frequency). Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis Effects of Chest Physiotherapy (CPT) on Lung Clearance Index (LCI) in Non Cystic Fibrosis (CF) Bronchiectasis Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR) Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis Physiological Effects of Expiration With the Glottis Open in Lateral Posture (ELTGOL) and Flutter Valve in Patients With Bronchiectasis Comparison of the Efficacy of Comprehensive Respiratory Physiotherapy in Children With Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa. Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis Sputum Clearance Effects of Hypertonic Saline in Non-cystic Fibrosis Bronchiectasis Safety and Efficacy of Bronchitol in Bronchiectasis Predictors of Physical Activity Performance and Dynamic Hyperinflation in Patients With Bronchiectasis Oscillating PEP vs Autogenic Drainage in People With Bronchiectasis Feasibility of Interval Exercise in Bronchiectasis Prognosis of Bronchiectasis in Children–A Multicenter Prospective Cohort Study Exercise Training in Patients With Non-cystic Fibrosis (CF) Bronchiectasis Effects of Inspiratory Muscle Training in Patients With Bronchiectasis Acute Effects of a Flutter Device and Chest Wall Compression on Respiratory System Impedance in Bronchiectasis Patients Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis Cardiovascular Comorbidities and Bronchiectasis The Effect of Different Virtual Reality-Based Exercise Trainings on Pulmonary Function, Respiratory and Peripheral Muscle Strength, Functional Capacity and Balance in Children With Bronchiectasis Functional Respiratory Imaging in Bronchiectasis Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non‐Cystic Fibrosis Bronchiectasis Long-term Prognosis of Children With Bronchiectasis Treated With Low-dose Erythromycin Intervention Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial Respiratory Mechanics Effects of Flutter Valve in Bronchiectasis Patients Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Feasibility Study of the AffloVest in Bronchiectasis Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa The Effect of Theophylline in the Treatment of Bronchiectasis Bronchiectasis and Long Term Azithromycin Treatment Clinimetric Properties of Outcome Measures in Bronchiectasis in the UK Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Pain Mechanisms in Patients With Bronchiectasis Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis A Study to Access Safety and Efficacy of Nebulized Tobramycin in Patients With Bronchiectasis Bronchoalveolar Lavage for Bronchiectasis Patients With Exacerbation Efficacy of Azithromycin in Treatment of Bronchiectasis Airway Clearance in Bronchiectasis: is Non-Invasive Ventilation a Useful Adjunct in Moderate to Severe Disease? Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis Efficacy of Budesonide-Formoterol in Bronchiectasis Exhaled Breath Condensate Assessment in Stable Non-Cystic Fibrotic Bronchiectasis Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Long-term Airway Clearance Therapy in Non-cystic Fibrosis Bronchiectasis Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis Mucus Solids Concentration in Patients With Bronchiectasis Target Validation and Discovery in Idiopathic Bronchiectasis Exercise Capacity in Bronchiectasis Resection Physical Activity in Bronchiectasis The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis Effect of AIRVO Heated Humidification in Bronchiectasis A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis Lung Dispersing, Turbid Descending and Gut Clearing Decoction for Bronchiectasis Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis? Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis Autologous Transplantation of Bronchial Basal Cells for Treatment of Bronchiectasis Efficacy and Safety of Hydrogen Inhalation on Bronchiectasis: A Randomized, Multi-center, Double-blind Study Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Bronchiectasis Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis Reaction Time and Postural Control in Individuals With Cystic Fibrosis and Bronchiectasis Impact of Chronic Air Pollution on Non-cystic Fibrosis Bronchiectasis Comparison of Physical Activity Level Between Patients With Bronchiectasis and Healthy Subjects Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Bronchiectasis Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis The Effect of Bronchiectasis on the Exacerbation and Mortality in COPD Inhaled A1AT in Adult Stable Bronchiectasis Prevention of Bronchiectasis in Infants With Cystic Fibrosis Pulmonary Rehabilitation in Non-Cystic Fibrosis Bronchiectasis Metabolomic Analysis of Exhaled Breath Condensates in Patients With COPD and Bronchiectasis Physical Capacity in Patients With Bronchiectasis Before and After Rehabilitation Program In-exsufflator Cough Assist Device in Patients With Symptomatic Bronchiectasis Bronchiectasis Effect in COPD Patients Prevalence and Characteristics of Patients With Bronchiectasis Comorbid Nontuberculous Mycobacteria Aetiology of Children With Bronchiectasis in China Macrolides in COPD- Bronchiectasis Overlap Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis Comparison of Sit-to-stand Test With Six-minute Walk Test in Bronchiectasis and Healthy Children Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls The PROspective German NOn-CF bronchiectaSIS Patient Registry The BRIDGE Study – Bronchiectasis Research Involving Databases, Genomics and Endotyping Role of Innate Immunity in Non-Cystic Fibrosis Bronchiectasis Exercise Capacity in Patients With Cystic Fibrosis vs. Non-cystic Fibrosis Bronchiectasis Evaluation of Medical and Nursing Management for Bronchiectasis A Pilot Study to Evaluate the Use of the Vest® System for Treatment of Bronchiectasis Patients in the Home Setting The Establishment of China Bronchiectasis Registry and Research Collaboration Short-and Long-term Effects of a Home-based Rehabilitation Program in Patients With Bronchiectasis The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults Bronchiectasis: Evaluation of an Educational Intervention Prevalence of Bronchiectasis in COPD Patients ELTGOL and Bronchiectasis. Respiratory Therapy Bacteriology and Inflammation in Bronchiectasis Different Phenotypes of Bronchiectasis Effects of Traditional Chinese Medicine on Bronchiectasis Patients The Prevalence and Impact of Depression and Anxiety Symptoms in Patients With Non-CF Bronchiectasis

Brief Title

The SENSOR Study: A Mixed-methods Study of SElf-management Checks to Predict exacerbatioNs of Pseudomonas Aeruginosa in Patients With Long-term reSpiratORy Conditions

Official Title

The SENSOR Study: A Mixed-methods Study of SElf-management Checks to Predict exacerbatioNs of Pseudomonas Aeruginosa in Patients With Long-term reSpiratORy Conditions

Brief Summary

      The World Health Organisation predicts that lung disease will be the World's third largest
      killer in the future. This research project is looking to see whether the concept of a "home
      hospital" using the latest gadgets and iPad technology, can help patients stay well and out
      of hospital.

      Portsmouth Hospitals Trust is collaborating with a Company based in the United Kingdom (UK)
      who has developed a test to predict when people with lung diseases, such as; asthma, COPD and
      bronchiectasis, who regularly have chest infections, are about to become poorly with another
      infection - a form of early warning system. The investigators hope that the test will
      eventually be able to be used by the patient at home daily, to help self-manage their
      condition. The test measures whether bacteria are present, in sputum, and in what quantity.
      This information can be used by the patient's healthcare team to consider providing treatment
      earlier, thus controlling the infection sooner and reducing the patient's symptoms so that
      patients can stay at home rather than being regularly admitted to hospital.

      Part of this "early warning system" that has been developed by the UK Company includes the
      daily measurement of a number of indicators of health. These are usually only measured in
      hospital or by a General Practitioner, but new devices have been made that are simple enough
      for everyone to use at home.

      The investigators will include 30 participants, with non-Cystic Fibrosis (CF) chronic
      respiratory conditions who will be asked to take daily measurements of their blood pressure,
      temperature, weight and how well their heart and lungs are working with easy-to-use devices.
      They will also measure their physically activity with an activity tracker and report their
      wellness and whether they have taken medication daily. Participants will also be asked to
      collect a sample of sputum and urine each morning. Taking the samples and measurements should
      only take between 5-15 minutes each day to carry out.

      The sputum and urine will be tested at the hospital and will be recorded and analysed, so
      that the researchers can learn what happens well before a person with these conditions falls
      sick and needs hospitalisation.

Detailed Description

      The purpose of this study is to see whether the concept of a "home hospital" using the latest
      gadgets and iPad technology, can help patients stay well and out of hospital.

      This trial is a single centre, non-randomised, mixed methods study. A longitudinal cohort of
      patients and their carers (where appropriate) will be asked to collect physiological,
      biological and disease outcome data over a 6 month period. Both participants and the
      clinicians responsible for patient care and will have no access to the longitudinal data and
      this information will not be used to make clinical decisions. The laboratory samples will
      also be analysed in a blinded manner. These data will then be analysed to develop a model for
      predicting onset of exacerbations which can be built into a self-monitoring system.

      Qualitative methods will be used to explore participant and carer experiences of using the
      technology and performing daily self-monitoring assessments. The expected duration of
      participant participation in the cohort will be six months, with an invitation to complete a
      self-administered questionnaire at baseline to inform a face to face semi-structured
      interview with patients with, or without carer joint participant at the end of the follow-up
      period (six months completion).

      A total of 30 male and female patients, aged 18 and over will be recruited;

      20 patients chronically infected with Pseudomonas Aeruginosa (PA):

      • 10 with asthma or COPD and 10 with non-CF bronchiectasis

      10 patients with no previously detected PA infection, infected with Haemophilus influenza

      The investigators will also recruit 10 patients plus/minus their carers from the PA group, 5
      patients plus/minus their carers from the HI group into the qualitative part of the study.


      Potential participants will be recruited from existing asthma, COPD and non-CF bronchiectasis
      local patient databases in combination with the local laboratory results systems by the
      clinical care team. Potential participants identified will then be contacted by a member of
      the local research team who are also the routine clinical care team and invited to attend a
      specialist research recruitment clinic.

      At the research clinic participants will be reviewed by a clinical research fellow and
      screened for suitability for the study by the research team. Patients and carers will be able
      to view and try out the self-monitoring devices and tablet-based IT system. Capacity to
      operate these systems will be assessed as part of the screening. Those who meet eligibility
      criteria will be given a Participant Information Sheet and/or Carer information sheet if
      participants wish for their carer to assist them in using the self-monitoring devices and
      tablet-based IT system daily.

      After adequate time to consider and ask questions about the study, participants who are
      interested in taking part in the trial will be invited to a screening visit where they will
      be asked to sign a consent form.

      At the screening visit, following consent, participants' lung function, blood pressure,
      oxygen levels, height, weight and BMI will be recorded and general health questions will be
      asked to gain information on medical history, current medications & smoking status.
      Participants will also be asked to complete a set of baseline questionnaires.

      Following the screening visit (up to 10 days after), the research nurse and an technician
      from the company ASEPTIKA will deliver and install the study equipment into the participants
      home and train the participant on how to use all the technology provided. This training visit
      will take approximately 60 minutes.

      Over a period of 6 months, participants will be required to collect a sputum and urine sample
      daily and store them in the freezer provided, in their own homes. Participants will be
      trained in sample collection at the screening visit by a member of the research team. The
      samples will be collected from the participants monthly by the a member of the research team,
      or participants can bring the samples into hospital at their routine clinic appointments.
      Participants will also need to measure their weight, blood pressure, oxygen level and lung
      function and wear an activity monitor daily. These results, as well as a questionnaire, are
      recorded on the iPad which sends the data via 3G to a central database. The process should
      take no longer than 15 minutes a day. Participants and clinicians will be blind to the
      continuous data over the duration of the study but participants will see the values generated
      daily on the screens of the devices.

      During the study participants will attend their normal review with the medical team at 3 and
      6 months (study completion) which usually involves lung function, sputum sample for culture
      and clinical review. These visits will coincide with a short clinic visit to see the research
      team to complete disease specific and quality of life questionnaires as well as noting any
      changes to treatment and exacerbations.

      Participants and their carers will also have the opportunity to give additional consent to
      take part in a qualitative interview, at the same time as the main study consent is sought.
      If consent is attained, participants will be given an extra questionnaire to complete at
      baseline which will include questions on their expectations and desired outcomes of the
      study, worries, concerns and any foreseen barriers to compliance. Participants plus or minus
      their carers may then be selected and invited to take part in 1 semi-structured face-to-face
      interview, at the end of study (6 months) to discuss what they think about the study and also
      what they feel and understand about their health. The interviews will either be conducted at
      the participants' homes or at hospital, depending on their preference and will be conducted
      by the same research fellow throughout the study to allow consistency. The interviews will
      take approximately 45-60 minutes depending on what the participant/carer wishes to share. The
      interview can be terminated at any point the participant/carer wishes to stop and this will
      not influence their subsequent treatment.

      If participants are admitted to hospital during the course of the study they will be asked to
      take along their iPad and self-monitoring devices with them. If participants forget their
      iPad a member of the study team will visit the patient on the ward and will assist to collect
      the patient's daily measurements for the study where appropriate.

Study Type


Primary Outcome


Secondary Outcome

 Treatment Efficacy


Chronic Obstructive Pulmonary Disease (COPD)


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

August 2014

Completion Date

March 2017

Primary Completion Date

March 2015

Eligibility Criteria

        Inclusion Criteria:

          -  Male or Female, aged 18 years or above.

          -  Diagnosed with at least one (or a combination) of the following chronic respiratory
             conditions: asthma, COPD, non-CF bronchiectasis.

          -  Previous positive bacterial culture for PA or HI.

          -  Two or more exacerbations treated with antibiotics with the same pathogen within the
             last 12 months, one of which must have been within the last 6 months.

          -  Has been exacerbation free for the previous 4 weeks.

          -  Producing at least 1ml of sputum daily.

          -  Must be capable of operating the self-monitoring devices and tablet-based IT system,
             or have a carer capable of undertaking the measurements and collection, storage and
             transport of samples.

          -  Participant is willing and able to give informed consent for participation in the

        Exclusion Criteria:

          -  A suspected or confirmed diagnosis of Cystic Fibrosis

          -  Any condition likely to limit participant survival or adherence during the study
             period in the judgement of the clinician, for example malignancy, cirrhosis of the

          -  Currently taking part in any other research study.




18 Years - N/A

Accepts Healthy Volunteers



Prof Anoop Chauhan, , 

Location Countries

United Kingdom

Location Countries

United Kingdom

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Portsmouth Hospitals NHS Trust


 University of Portsmouth

Study Sponsor

Prof Anoop Chauhan, Principal Investigator, Portsmouth Hospitals NHS Trust

Verification Date

January 2017